Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events.
Vera E R AsscherQuirine van der VlietKaren van der AalstAnniek van der AalstEelco C BrandAndrea E van der Meulen-de JongBas OldenburgMarieke J PierikBas van TuylNofel MahmmodP W Jeroen MaljaarsHerma H Fiddernull nullPublished in: International journal of colorectal disease (2020)
Older patients receiving anti-TNF therapy have a higher risk of serious infections compared with older IBD patients without anti-TNF therapy, but not compared with younger patients receiving anti-TNF therapy. However, in anti-TNF-exposed patients, comorbidity was found to be an indicator with regards to SAEs. Effectiveness was comparable between older and younger patients.